Severe Acne Vulgaris Pipeline Analysis Report 2025
Description
Acne vulgaris is a common occurrence in both young adults and adolescents. The prevalence rates range from 35-90% in adolescents. Moreover, 12% of the women and 3% of the men aged over 25 may also develop the condition. Hence, researchers and key healthcare companies are focused on creating a range of highly effective drugs that cater to a wider cohort of patients. This influences the drug pipeline significantly.
Report Coverage
The Severe Acne VulgarisDrug Pipeline Insight Report by Expert Market Research gives comprehensive insights into severe acne vulgaris drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for severe acne vulgaris. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The severe acne vulgaris pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from severe acne vulgaris.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to severe acne vulgaris.
Severe Acne Vulgaris Pipeline Outlook
Acne vulgaris is a chronic form of acne, characterized by the formation of inflammatory or non-inflammatory skin lesions. It commonly affects the face, but it may spread to the neck, back or chest in some cases. It is commonly triggered by a bacterial species called Cutibacterium acnes and mostly affects young adults. Common symptoms include excessive sebum production, follicular plugging with keratinocytes and colonization by the bacteria. Hormonal imbalance, high sweating, occlusive cosmetics or skin care can be other causes of acne vulgaris.
Treatment for severe acne vulgaris depends on skin type, area and type of lesions as well as grade of acne. Acne is graded in the severe category when the total lesion count is more than 125, the total inflammatory count is greater than 50 and the total comedo is higher than 100. In October 2023, Bausch Health’s Cabtreo (triple combination gel) for treating acne in individuals aged 12 or above. Such drug approvals are expected to stimulate more research, thereby, impacting the drug pipeline for severe acne vulgaris positively.
Severe Acne Vulgaris – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of severe acne vulgaris drugs based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for severe acne vulgaris. There are around 47 drugs in phase II of severe acne vulgaris drugs.
Severe Acne Vulgaris – Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under severe acne vulgarispipeline analysis include antibiotics, retinoids, hormonal agents, and anti-inflammatory drugs. Antibiotics like doxycycline, minocycline, and tetracycline may be advised for treating bacterial infections while anti-inflammatory drugs such as corticosteroids can be taken orally or injected into the acne lesion. Drugs are based on the patient’s profile and the severity of the condition.
Severe Acne VulgarisClinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the severe acne vulgarisdrug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in severe acne vulgaris clinical trials:
PF-05175157
Pfizer's PF-05175157 is in Phase 2 of a 6-week randomized, double-blind, placebo-controlled study. It is under evaluation for its safety and tolerability against treating moderate to severe acne vulgaris in adults.
RA-18C3
RA-18C3 is a human monoclonal antibody, currently in Phase 2 of a 91-day open label trial for treating moderate to severe acne vulgaris in subjects. Sponsored by Janssen Research & Development, LLC, the participants will receive doses on days 0, 21, and 42 (with a total of 3 injections).
FMX101
FMX101 is a topical foam that contains 4% minocycline. Sponsored by Vyne Therapeutics, Inc., it is Phase 3 of a randomized, double-blind, vehicle-controlled study to investigate its safety and efficacy for treating moderate-to-severe acne vulgaris.
Topical SB204
Sponsored by Novan Inc., it is Phase 1 of a single-center, open-label study. The topical is under investigation to treat adolescents with moderate to severe acne vulgaris. The study involves taking blood samples from the participants on Day 1 and Day 21 to characterize systemic exposure to hMAP3 and nitrate.
Reasons To Buy This Report
The Severe Acne Vulgaris Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for severe acne vulgaris. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within severe acne vulgaris pipeline insights.
Key Questions Answered in the Severe Acne Vulgaris– Pipeline Insight Report
Global Severe Acne Vulgaris Treatment Market
Acne Therapeutics Market
Global Clinical Trials Market
Report Coverage
The Severe Acne VulgarisDrug Pipeline Insight Report by Expert Market Research gives comprehensive insights into severe acne vulgaris drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for severe acne vulgaris. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The severe acne vulgaris pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from severe acne vulgaris.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to severe acne vulgaris.
Severe Acne Vulgaris Pipeline Outlook
Acne vulgaris is a chronic form of acne, characterized by the formation of inflammatory or non-inflammatory skin lesions. It commonly affects the face, but it may spread to the neck, back or chest in some cases. It is commonly triggered by a bacterial species called Cutibacterium acnes and mostly affects young adults. Common symptoms include excessive sebum production, follicular plugging with keratinocytes and colonization by the bacteria. Hormonal imbalance, high sweating, occlusive cosmetics or skin care can be other causes of acne vulgaris.
Treatment for severe acne vulgaris depends on skin type, area and type of lesions as well as grade of acne. Acne is graded in the severe category when the total lesion count is more than 125, the total inflammatory count is greater than 50 and the total comedo is higher than 100. In October 2023, Bausch Health’s Cabtreo (triple combination gel) for treating acne in individuals aged 12 or above. Such drug approvals are expected to stimulate more research, thereby, impacting the drug pipeline for severe acne vulgaris positively.
Severe Acne Vulgaris – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of severe acne vulgaris drugs based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:
- Antibiotics
- Retinoids
- Hormonal Agents
- Anti-inflammatory Drugs
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Topical
- Others
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for severe acne vulgaris. There are around 47 drugs in phase II of severe acne vulgaris drugs.
Severe Acne Vulgaris – Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under severe acne vulgarispipeline analysis include antibiotics, retinoids, hormonal agents, and anti-inflammatory drugs. Antibiotics like doxycycline, minocycline, and tetracycline may be advised for treating bacterial infections while anti-inflammatory drugs such as corticosteroids can be taken orally or injected into the acne lesion. Drugs are based on the patient’s profile and the severity of the condition.
Severe Acne VulgarisClinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the severe acne vulgarisdrug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in severe acne vulgaris clinical trials:
- Allergan
- Novartis Pharmaceuticals
- Pfizer
- Incyte Corporation
- AbbVie
- UCB Biopharma SRL
- Janssen Research & Development, LLC
- Almirall, S.A.
- Vyne Therapeutics Inc.
- LEO Pharma
PF-05175157
Pfizer's PF-05175157 is in Phase 2 of a 6-week randomized, double-blind, placebo-controlled study. It is under evaluation for its safety and tolerability against treating moderate to severe acne vulgaris in adults.
RA-18C3
RA-18C3 is a human monoclonal antibody, currently in Phase 2 of a 91-day open label trial for treating moderate to severe acne vulgaris in subjects. Sponsored by Janssen Research & Development, LLC, the participants will receive doses on days 0, 21, and 42 (with a total of 3 injections).
FMX101
FMX101 is a topical foam that contains 4% minocycline. Sponsored by Vyne Therapeutics, Inc., it is Phase 3 of a randomized, double-blind, vehicle-controlled study to investigate its safety and efficacy for treating moderate-to-severe acne vulgaris.
Topical SB204
Sponsored by Novan Inc., it is Phase 1 of a single-center, open-label study. The topical is under investigation to treat adolescents with moderate to severe acne vulgaris. The study involves taking blood samples from the participants on Day 1 and Day 21 to characterize systemic exposure to hMAP3 and nitrate.
Reasons To Buy This Report
The Severe Acne Vulgaris Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for severe acne vulgaris. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within severe acne vulgaris pipeline insights.
Key Questions Answered in the Severe Acne Vulgaris– Pipeline Insight Report
- What is the current landscape of severe acne vulgaris pipeline drugs?
- How many companies are developing severe acne vulgaris drugs?
- How many phase III and phase IV drugs are currently present in severe acne vulgaris pipeline drugs?
- Which companies/institutions are leading the severe acne vulgaris drug development?
- What is the efficacy and safety profile of severe acne vulgaris pipeline drugs?
- What are the opportunities and challenges present in the severe acne vulgaris drug pipeline landscape?
- Which company is conducting major trials for severe acne vulgaris drugs?
- What geographies are covered for severe acne vulgaris clinical trials?
- What are emerging trends in severe acne vulgaris clinical trials?
Global Severe Acne Vulgaris Treatment Market
Acne Therapeutics Market
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology and Assumptions
- 2 Executive Summary
- 3 Overview of Severe Acne Vulgaris
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Severe Acne Vulgaris: Epidemiology Snapshot
- 5.1 Severe Acne Vulgaris Incidence by Key Markets
- 5.2 Severe Acne Vulgaris– Patients Seeking Treatment in Key Markets
- 6 Severe Acne Vulgaris: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Severe Acne Vulgaris: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Severe Acne Vulgaris, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Severe Acne Vulgaris Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Severe Acne Vulgaris Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 FMX101
- 10.2.3 Other Drugs
- 11 Severe Acne Vulgaris Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 CTX-4430
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 RA-18C3
- 11.2.3 PF-05175157
- 11.2.4 Other Drugs
- 12 Severe Acne Vulgaris Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 SB204 4%
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Severe Acne Vulgaris Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Drug 2
- 13.2.3 Other Drugs
- 14 Severe Acne Vulgaris, Key Drug Pipeline Companies
- 14.1 Allergan
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Novartis Pharmaceuticals
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Pfizer
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Incyte Corporation
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 AbbVie
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 UCB Biopharma SRL
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Janssen Research & Development, LLC
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Almirall, S.A.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 Vyne Therapeutics Inc.
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 14.10 LEO Pharma
- 14.10.1 Company Snapshot
- 14.10.2 Pipeline Product Portfolio
- 14.10.3 Financial Analysis
- 14.10.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
